How should hyperkalemia be treated, especially when serum potassium is ≥6.5 mmol/L or ECG changes are present?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Treatment of Hyperkalemia

For severe hyperkalemia (≥6.5 mmol/L) or any hyperkalemia with ECG changes, immediately administer IV calcium (calcium chloride 500-1000 mg or calcium gluconate 1.5-3 g over 2-5 minutes) to stabilize the myocardial membrane, followed by insulin with glucose and nebulized albuterol to shift potassium intracellularly. 1

Immediate Management Algorithm

Step 1: Cardiac Membrane Stabilization (Within 1-3 minutes)

  • Calcium chloride 10%: 5-10 mL (500-1000 mg) IV over 2-5 minutes, OR
  • Calcium gluconate 10%: 15-30 mL IV over 2-5 minutes 1

This is the first-line intervention when potassium ≥6.5 mmol/L or ECG changes are present (peaked T waves, flattened P waves, prolonged PR interval, widened QRS complex). Calcium does not lower potassium but protects against cardiac arrhythmias and sudden death 1.

Step 2: Shift Potassium Intracellularly (Within 30-60 minutes)

Administer simultaneously (not sequentially):

  • Insulin + Glucose: Mix 10 units regular insulin with 25 g glucose (50 mL of D50) IV over 15-30 minutes 1
  • Nebulized albuterol: 10-20 mg in 4 mL nebulized over 15 minutes 1

Critical caveat: These therapies are temporary (lasting 1-4 hours) and do not remove potassium from the body—rebound hyperkalemia can occur after 2 hours 2, 3. Monitor blood glucose post-insulin; hypoglycemia occurs in 21-24% of patients, yet glucose monitoring is often inadequately documented 4.

  • Sodium bicarbonate: 50 mEq IV over 5 minutes—only if metabolic acidosis is present 1, 2. Its efficacy as monotherapy is poor 2.

Step 3: Remove Potassium from the Body

Begin potassium elimination measures immediately after stabilization:

  • Loop diuretics: Furosemide 40-80 mg IV (only effective if patient has residual kidney function and is not oliguric) 1
  • Potassium binders:
    • Sodium polystyrene sulfonate (Kayexalate): 15-50 g with sorbitol PO or PR 1
    • Newer agents (patiromer or sodium zirconium cyclosilicate): More effective for chronic management and allow continuation of RAASi therapy 2, 5
  • Hemodialysis: For resistant acute hyperkalemia, oliguria, or end-stage renal disease 1, 6

Severity Classification and ECG Monitoring

The 2010 AHA guidelines define severe hyperkalemia as >6.5 mmol/L 1, though the ESC uses >6.0 mmol/L as the threshold for severe hyperkalemia 2. Continuous cardiac monitoring is mandatory for potassium ≥6.0 mmol/L 7, 6.

Important pitfall: Absent or atypical ECG changes do not exclude the need for immediate intervention 3. ECG changes are actually uncommon even in severe hyperkalemia 4, yet life-threatening arrhythmias can occur at variable thresholds between patients 2.

Special Considerations

Cardiac Arrest Due to Hyperkalemia

When cardiac arrest occurs secondary to hyperkalemia, administer the adjuvant IV therapies outlined above (calcium, insulin/glucose, albuterol, bicarbonate if acidotic) in addition to standard ACLS protocols 1.

Monitoring Requirements

  • Repeat potassium measurement within 1-2 hours after initial treatment to detect rebound hyperkalemia 2, 3
  • Check blood glucose 15-30 minutes after insulin administration 4
  • Reassess potassium within 1 week for patients with chronic hyperkalemia risk 6

Long-Term Prevention

The final critical step is preventing recurrence 3:

  • Identify and address underlying causes (renal failure, medications, tissue breakdown)
  • Review all medications that increase potassium (RAASi, NSAIDs, potassium-sparing diuretics, trimethoprim) 2
  • Consider newer potassium binders to enable continuation of life-saving RAASi therapy in patients with heart failure or CKD 2, 8, 5

Key principle: Do not discontinue RAASi therapy for mild-moderate hyperkalemia without first attempting potassium-lowering strategies, as RAASi provide mortality benefit in cardiovascular disease 2, 8.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.